INGELHEIM, Germany - Monday, June 17th 2013 [ME NewsWire]

    Published online in Circulation, results from RELY-ABLE®, the RE-LY® extension study, support long-term safety of Pradaxa® (dabigatran etexilate) in patients with non-valvular atrial fibrillation
    Pradaxa® is the only novel oral anticoagulant with controlled long-term clinical trial data extending beyond 4 years of ongoing treatment
    The long-term results contribute to the growing body of data reinforcing Pradaxa® as an important advancement in the treatment of patients with atrial fibrillation compared to warfarin1

(BUSINESS WIRE)-- For media outside of the US, the UK & Canada only

New long-term data from the RELY-ABLE® study, the long-term extension of the pivotal RE-LY®i trial of Pradaxa® (dabigatran etexilate) in patients with non-valvular atrial fibrillation (AF), were today published online in Circulation,1 ... Read more »

Introduction of the world's first MFP and Barcode Printer line up with re-usable paper; focus on optimal management transparency with smart sustainable business solution

TOKYO - Monday, June 17th 2013 [ME NewsWire]

(BUSINESS WIRE/ME NewsWire)-- TOSHIBA TEC (TOKYO:6588) today unveiled its 2013-2015 global business strategy for its Printing Solutions Business with a strong emphasis on the Retail & Hospitality industry.

Toshiba TEC's Printing Solution Business will introduce its innovative new solutions line up to leading retailers already working with Toshiba Global Commerce Solutions, the world's leading supplier of integrated in-store solutions.

As part of this new mid-term business plan, Toshiba TEC will offer the world's first ECO-friendly MFP systems as its Next Generation MFP flagship series. In order to evolve into one of the world's foremost eco-companies, Toshiba has been accelerating its environmental management, and works hard to find a careful ... Read more »

Treatment indicated for patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS) with an isolated chromosomal abnormality called deletion 5q

BOUDRY, Switzerland - Monday, June 17th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Celgene International Sàrl (NASDAQ: CELG) was today notified that the European Commission (EC) has amended the marketing authorisation for REVLIMID®. This decision means that REVLIMID is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.1

MDS is a type of cancer where the production of blood cells and platelets by the bone marrow is disrupted, which can often lead to severe anaemia, infections and bleeding.2 Approximately 50 percent of individuals with MDS will have some form of chromosome (cytogenetic) abnormality, ... Read more »